NASDAQ:PDSB PDS Biotechnology (PDSB) Stock Forecast, Price & News $4.95 -0.08 (-1.59%) (As of 01:21 PM ET) Add Compare Share Share Today's Range$4.88▼$5.1050-Day Range$4.80▼$6.4052-Week Range$2.89▼$13.65Volume282,294 shsAverage Volume624,178 shsMarket Capitalization$152.81 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media PDS Biotechnology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside246.2% Upside$17.00 Price TargetShort InterestBearish14.80% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.01Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.54) to ($1.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.59 out of 5 starsMedical Sector890th out of 970 stocksPharmaceutical Preparations Industry418th out of 453 stocks 3.5 Analyst's Opinion Consensus RatingPDS Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, PDS Biotechnology has a forecasted upside of 246.2% from its current price of $4.91.Amount of Analyst CoveragePDS Biotechnology has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.80% of the outstanding shares of PDS Biotechnology have been sold short.Short Interest Ratio / Days to CoverPDS Biotechnology has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in PDS Biotechnology has recently increased by 6.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPDS Biotechnology does not currently pay a dividend.Dividend GrowthPDS Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PDSB. Previous Next 2.8 News and Social Media Coverage News SentimentPDS Biotechnology has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for PDS Biotechnology this week, compared to 2 articles on an average week.Search Interest7 people have searched for PDSB on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows6 people have added PDS Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PDS Biotechnology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.00% of the stock of PDS Biotechnology is held by insiders.Percentage Held by InstitutionsOnly 25.78% of the stock of PDS Biotechnology is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for PDS Biotechnology are expected to decrease in the coming year, from ($1.54) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PDS Biotechnology is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PDS Biotechnology is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPDS Biotechnology has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About PDS Biotechnology (NASDAQ:PDSB) StockPDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.Read More PDSB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PDSB Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comPDS Biotech to Present at the LD Micro Main Event XVISeptember 25, 2023 | finance.yahoo.comPDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101September 29, 2023 | PressReach (Ad)This Stock's a Sleeping GiantThe stock everyone has their eye on - discover why it's the talk of the investment world. September 22, 2023 | americanbankingnews.comPDS Biotechnology (NASDAQ:PDSB) Stock Rating Reaffirmed by HC WainwrightSeptember 20, 2023 | finance.yahoo.comPDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 20, 2023 | finance.yahoo.comPDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical StudiesSeptember 13, 2023 | finance.yahoo.comPDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023September 6, 2023 | finance.yahoo.comPDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 29, 2023 | PressReach (Ad)This Stock's a Sleeping GiantThe stock everyone has their eye on - discover why it's the talk of the investment world. September 6, 2023 | finance.yahoo.comPDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI ConferenceSeptember 3, 2023 | fool.comPDS Biotechnology (NASDAQ: PDSB)August 16, 2023 | finance.yahoo.comPDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual MeetingAugust 15, 2023 | markets.businessinsider.comPDS Biotechnology (PDSB) Gets a Buy from Noble FinancialAugust 15, 2023 | finance.yahoo.comQ2 2023 PDS Biotechnology Corp Earnings CallAugust 14, 2023 | seekingalpha.comThe Prognosis For PDS BiotechnologyAugust 14, 2023 | finanznachrichten.dePDS Biotechnology Corporation: PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 14, 2023 | finance.yahoo.comPDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 TrialAugust 14, 2023 | finance.yahoo.comPDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 14, 2023 | msn.comPDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 StudyAugust 11, 2023 | benzinga.comPDS Biotechnology Earnings PreviewAugust 7, 2023 | finance.yahoo.comPDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial ResultsAugust 2, 2023 | finance.yahoo.comPDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023July 26, 2023 | benzinga.comPDS Biotechnology – Top-Line Data From Its Lead Candidate Points To Promising Future For This CompanyJuly 25, 2023 | finance.yahoo.comPDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023July 17, 2023 | finance.yahoo.comPDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023July 11, 2023 | finance.yahoo.comPDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301July 1, 2023 | finanznachrichten.dePDS Biotechnology Corporation: PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive PDSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address PDSB Company Calendar Last Earnings8/14/2023Today9/29/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PDSB CUSIPN/A CIK1472091 Webwww.pdsbiotech.com Phone(800) 208-3343Fax908-790-1212Employees26Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$21.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+238.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-116.11% Return on Assets-67.24% Debt Debt-to-Equity Ratio0.72 Current Ratio8.02 Quick Ratio8.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book3.25Miscellaneous Outstanding Shares30,870,000Free Float27,781,000Market Cap$155.28 million OptionableNot Optionable Beta1.93 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Frank K. Bedu-Addo Ph.D. (Age 58)Pres, CEO & Director Comp: $854.1kMr. Matthew C. Hill CPA (Age 54)CFO, Principal Financial & Accounting Officer Comp: $504.09kMs. Lauren V. Wood M.D. (Age 63)Chief Medical Officer Comp: $568.5kDr. Joe J. DervanVP of R&DDr. Gregory L. Conn Ph.D. (Age 68)Chief Scientific Officer Ms. Deanne RandolphVP of Commercial Devel. & Head of Investor RelationsMr. Spencer Brown J.D. (Age 53)Sr. VP & Gen. Counsel Ms. Nathalie RiebelSr. VP of Clinical OperationsMr. Sanjay ZaveriSr. VP of Bus. Devel.Ms. Janetta Trochimiuk (Age 60)Controller More ExecutivesKey CompetitorsOncolytics BiotechNASDAQ:ONCYLianBioNASDAQ:LIANVerrica PharmaceuticalsNASDAQ:VRCAMereo BioPharma GroupNASDAQ:MREOApplied TherapeuticsNASDAQ:APLTView All CompetitorsInstitutional OwnershipBarclays PLCSold 33,684 shares on 9/21/2023Ownership: 0.018%California State Teachers Retirement SystemBought 9,301 shares on 8/21/2023Ownership: 0.030%Nuveen Asset Management LLCBought 105,201 shares on 8/16/2023Ownership: 0.341%Wells Fargo & Company MNBought 11,841 shares on 8/15/2023Ownership: 0.056%Kennedy Capital Management LLCBought 10,198 shares on 8/15/2023Ownership: 0.033%View All Institutional Transactions PDSB Stock - Frequently Asked Questions Should I buy or sell PDS Biotechnology stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PDSB shares. View PDSB analyst ratings or view top-rated stocks. What is PDS Biotechnology's stock price forecast for 2023? 3 Wall Street analysts have issued 12-month price objectives for PDS Biotechnology's stock. Their PDSB share price forecasts range from $12.00 to $21.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 238.0% from the stock's current price. View analysts price targets for PDSB or view top-rated stocks among Wall Street analysts. How have PDSB shares performed in 2023? PDS Biotechnology's stock was trading at $13.20 at the beginning of 2023. Since then, PDSB stock has decreased by 61.9% and is now trading at $5.03. View the best growth stocks for 2023 here. When is PDS Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our PDSB earnings forecast. How were PDS Biotechnology's earnings last quarter? PDS Biotechnology Co. (NASDAQ:PDSB) issued its earnings results on Monday, August, 14th. The company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). What other stocks do shareholders of PDS Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other PDS Biotechnology investors own include Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Boxlight (BOXL), Otonomy (OTIC), Bionano Genomics (BNGO), CymaBay Therapeutics (CBAY), Cerecor (CERC), Enterprise Products Partners (EPD) and Evofem Biosciences (EVFM). What is PDS Biotechnology's stock symbol? PDS Biotechnology trades on the NASDAQ under the ticker symbol "PDSB." How do I buy shares of PDS Biotechnology? Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PDS Biotechnology's stock price today? One share of PDSB stock can currently be purchased for approximately $5.03. How much money does PDS Biotechnology make? PDS Biotechnology (NASDAQ:PDSB) has a market capitalization of $155.28 million. The company earns $-40,850,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. How can I contact PDS Biotechnology? PDS Biotechnology's mailing address is 25B Vreeland Road, Florham Park NJ, 07932. The official website for the company is www.pdsbiotech.com. The company can be reached via phone at (800) 208-3343, via email at ir@edgetherapeutics.com, or via fax at 908-790-1212. This page (NASDAQ:PDSB) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.